CDK8 and metastatic neoplasm: Although the effect of CDK8/19i on the metastatic burden was not directly measured in our study, the observed significant extension of metastatic disease survival found in the 4T1 model, coupled with prior results, indicates the potential of the CDK8/19i for the treatment of TNBC lung metastases, a major cause of lethality in this disease.